INDV
IndiviorANasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-06-02
Current thesis
Bull case: successful continuation of US commercial momentum and improved payer coverage drive >25% upside within 6–12 months as revenue/margin mix improves and valuation multiple re-rates.
Posture
Constructive
Lead driver
Momentum
What changed
Momentum remains the lead driver in the composite, 7D delta -7.3.
What can break
Bear case: regulatory or litigation setbacks, or rapid generic entry, drive material downside (>25%) as revenue shocks and multiple compression occur.
Momentum
78
Value
64
Sentiment
52
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $33.36 · Bull $45.66 · Bear $26.34
Data freshness
Prices
As of 2026-06-02
Fundamentals
As of 2026-06-01 • Vendor: Data Vendor v1
Scores
As of 2026-06-02 • Model: HYBRID_IC_RP
AI Memo
As of 2025-12-07 • Model: RankAlpha Sentiment AI
Investment thesisAs of 2026-06-02
Investment thesis
As of 2026-06-02
Supporting evidence
What
Grade A · Constructive
Confidence Medium · Net Neutral
Target $46.86
Why
Momentum78 · Δ7d -7.3
Value64 · Δ7d +0.8
Sentiment52 · Δ7d +10.2
So what
Strength-led posture (Net Neutral). Favor watchlist adds and disciplined entries.
Lead driver: Momentum · See technicals
Momentum
78
34% active weight
Current posture
7d trendSoftening
Δ7d
-7.3
Δ21d
-11.0
Value
64
32% active weight
Current posture
7d trendFlat
Δ7d
+0.8
Δ21d
+1.1
Sentiment
52
33% active weight
Current posture
7d trendImproving
Δ7d
+10.2
Δ21d
+17.7
Why this grade
Composite grade A. Momentum 77.7 / Value 63.8 / Sentiment 51.7
Fundamentals (TTM)As of 2026-06-01
Fundamentals (TTM)
As of 2026-06-01
Market Cap
$4.25B
Beta
1.14
Shares Out
124.85M
P/E (TTM)
37.8
P/S (TTM)
3.84
P/FCF (TTM)
37.72
Rev YoY
+2.3%
EPS YoY
+96.8%
Gross Margin
+85.5%
Op Margin
+18.7%
Net Debt
$13M
Current Ratio
0.96
As of 2026-06-02 • Updated nightlySource: Internal modelMethodology